全文获取类型
收费全文 | 1210篇 |
免费 | 109篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 57篇 |
妇产科学 | 9篇 |
基础医学 | 86篇 |
口腔科学 | 29篇 |
临床医学 | 204篇 |
内科学 | 204篇 |
皮肤病学 | 12篇 |
神经病学 | 43篇 |
特种医学 | 242篇 |
外科学 | 101篇 |
综合类 | 22篇 |
预防医学 | 34篇 |
眼科学 | 8篇 |
药学 | 235篇 |
中国医学 | 5篇 |
肿瘤学 | 33篇 |
出版年
2023年 | 8篇 |
2022年 | 3篇 |
2021年 | 9篇 |
2020年 | 6篇 |
2019年 | 7篇 |
2018年 | 24篇 |
2017年 | 11篇 |
2016年 | 19篇 |
2015年 | 22篇 |
2014年 | 29篇 |
2013年 | 24篇 |
2012年 | 19篇 |
2011年 | 19篇 |
2010年 | 38篇 |
2009年 | 55篇 |
2008年 | 28篇 |
2007年 | 9篇 |
2006年 | 20篇 |
2005年 | 9篇 |
2004年 | 11篇 |
2003年 | 15篇 |
2002年 | 11篇 |
2001年 | 21篇 |
2000年 | 22篇 |
1999年 | 25篇 |
1998年 | 58篇 |
1997年 | 57篇 |
1996年 | 69篇 |
1995年 | 55篇 |
1994年 | 47篇 |
1993年 | 57篇 |
1992年 | 32篇 |
1991年 | 28篇 |
1990年 | 29篇 |
1989年 | 53篇 |
1988年 | 51篇 |
1987年 | 47篇 |
1986年 | 48篇 |
1985年 | 38篇 |
1984年 | 29篇 |
1983年 | 24篇 |
1982年 | 28篇 |
1981年 | 24篇 |
1980年 | 15篇 |
1979年 | 13篇 |
1978年 | 8篇 |
1977年 | 14篇 |
1976年 | 13篇 |
1975年 | 17篇 |
1971年 | 2篇 |
排序方式: 共有1327条查询结果,搜索用时 31 毫秒
1.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
2.
Pharmacokinetics and hemodynamic effects of long-term nisoldipine treatment in hypertensive patients
J van Harten P van Brummelen M Danhof R P Quekel D D Breimer 《Journal of cardiovascular pharmacology》1989,13(4):624-629
In six patients with essential hypertension, the pharmacokinetics of nisoldipine were investigated before, during, and after 4 weeks of treatment. On day 1, nisoldipine was infused intravenously (i.v. 2 mg in 2 h); on day 2, oral nisoldipine treatment (10-mg tablets twice daily) was started for 4 weeks. During this period, patients came to the hospital six times, on which occasions blood samples were taken for the determination of trough and peak concentrations of nisoldipine. After 4-week treatment, the infusion experiment was repeated. In the first infusion experiment, systemic clearance was 1.02 +/- 0.23 L/min (mean +/- SD), terminal half-life (t1/2) was 15.4 +/- 6.7 h, and volume of distribution was 5.9 +/- 1.8 L/kg. After 4 weeks, these parameters had not changed significantly. Nisoldipine lowered blood pressure (BP) in all patients, whereas forearm blood flow and heart rate (HR) increased. Neither were the hemodynamic changes different after the oral treatment period, although basal BP was lower than before oral treatment. No accumulation of nisoldipine occurred during the 4-weeks treatment period. 相似文献
3.
4.
5.
Relationship between mephenytoin oxidation polymorphism and phenytoin, methylphenytoin and phenobarbitone hydroxylation assessed in a phenotyped panel of healthy subjects.
下载免费PDF全文
![点击此处可从《British journal of clinical pharmacology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
J H Schellens J H van der Wart D D Breimer 《British journal of clinical pharmacology》1990,29(6):665-671
1. In a phenotyped panel of healthy subjects correlations were studied between the oxidation of mephenytoin, phenytoin, methylphenytoin and phenobarbitone, with respect to the formation of their 4-hydroxy metabolites (OH-). 2. On different occasions phenotyped extensive metabolizers (EM; n = 16) and poor metabolizers (PM; n = 4) of mephenytoin received phenytoin (100 mg), methylphenytoin (100 mg) and phenobarbitone (50 mg) and urine was collected up to 24 h. The excreted 4-hydroxy metabolites of all compounds were measured by h.p.l.c. 3. Urinary recovery of OH-phenytoin was 31.0 +/- 11.7%, of OH-methylphenytoin 3.4 +/- 2.7% and of OH-phenobarbitone 1.4 +/- 1.2%. No correlation was found between the recovery of OH-mephenytoin and OH-phenytoin. A subject who produced virtually no OH-phenytoin was an EM of mephenytoin, confirming a dissociation of mephenytoin polymorphism and phenytoin hydroxylation. 4. The correlation coefficient for OH-mephenytoin and OH-methylphenytoin recovery was 0.71 (Spearman rank, P = 0.002). The PMs of mephenytoin excreted the least amount of OH-methylphenytoin, suggesting a cosegregation of the 4-hydroxylation pathways. No correlation was found between the urinary recovery of OH-phenobarbitone and that of the other 4-hydroxy metabolites. 相似文献
6.
7.
8.
9.
Pharmacokinetics of orally administered hexobarbital in plasma and saliva of healthy subjects 总被引:1,自引:0,他引:1
M van der Graaff N P Vermeulen P Heij J K Boeijinga D D Breimer 《Biopharmaceutics & drug disposition》1986,7(3):265-272
Hexobarbital (HB) concentrations were determined in plasma and saliva of 8 healthy subjects, following oral administration of 500 mg HB-Na. Mean plasma half-lives were 3.2 +/- 0.1 h, and salivary half-lives 3.3 +/- 0.2 h. Mean plasma clearance was 22.9 +/- 2.3 1 h-1. There was a linear relationship between HB concentrations in saliva and plasma (r = 0.92). Mean salivary levels were 34 per cent of plasma levels. Salivary pH was constant throughout the experiment, 7.06 +/- 0.09. There was an inconsistent tendency of the saliva over plasma ratios to increase as a function of time. The percentage of protein binding calculated from saliva over plasma ratios was in reasonable agreement with in vitro data of equilibrium dialysis, 64.1 +/- 2.6 per cent and 65.9 +/- 0.8 per cent, respectively. The experiment was repeated in 4 subjects, and considerable intraindividual differences were shown to exist in saliva over plasma ratio, half-lives, and protein binding. It was concluded that HB elimination half-lives can relatively accurately be determined from salivary concentrations. Oral plasma clearance can only be estimated if the individual saliva over plasma ratios are known; this would require the taking of at least one blood sample during the experiment. When employing HB as a model substrate for drug metabolizing enzyme activity in vivo, the determination of its pharmacokinetic parameters, particularly oral plasma clearance as a reflection of cytochrome P-450 activity, cannot be achieved by taking saliva samples only. 相似文献
10.